Recombinant DNA Technology: Definition, Steps and Applications

Recombinant DNA (rDNA) technology is a set of laboratory methods used to construct, modify, combine, copy and analyse DNA molecules. A recombinant DNA molecule contains a deliberately assembled DNA sequence that may combine fragments from different sources or include a synthetic or modified sequence. The technology is used in basic research, diagnostics, biotechnology, medicine, agriculture and food production. ¹²

I’m Julia Pizzolato, PhD, and I work at the intersection of protein engineering, antibody design and biomanufacturing analytics. At evitria, I support customers and project teams through technical consultation, feasibility assessments and training.

In this article, I explain the DNA-focused foundations of recombinant DNA technology and distinguish them from recombinant protein expression. My work at evitria focuses on recombinant antibody expression and protein production but in this article I also cover related fields such as molecular cloning, diagnostics, agriculture, GMOs and genome editing so that their boundaries remain clear.

Throughout this article, “recombinant DNA” refers to the engineered DNA construct. “Recombinant protein” refers to the product made when a suitable host expresses that construct. Often, recombinant DNA is used to study cellular functions without the need to purify a recombinant protein.

Recombinant DNA technology: definition and scope

Recombinant DNA (rDNA) technology comprises laboratory methods for constructing, combining, modifying, copying and analysing DNA molecules. A recombinant DNA molecule contains a deliberately assembled sequence, which may combine DNA fragments from different sources or include a synthetic or modified sequence. ¹²

Researchers use recombinant DNA to study genes, test regulatory sequences, create diagnostic reagents, and build DNA constructs for later applications. These methods include selecting or synthesising a sequence, assembling it in a vector, introducing it into a host cell, and verifying the resulting construct.

The technology is used across research, diagnostics, biotechnology, medicine, agriculture and food production. Its scope therefore includes many applications, from molecular cloning and recombinant protein production to genetically engineered organisms. The specific application determines which host organism, vector, safeguards and analytical methods are appropriate.

How does recombinant DNA technology work?

Recombinant DNA technology follows a sequence of design, assembly, propagation and verification steps. The exact workflow depends on whether the goal is to study DNA, copy a construct, express a protein or deliver a genetic payload.

Steps to produce recombinant DNA

1. Define the sequence and purpose

The researcher specifies the gene of interest, regulatory elements, tags or planned modifications.

2. Obtain the DNA

The sequence may be isolated from a biological source, amplified by PCR or chemically synthesised.

3. Choose a vector

A plasmid or another vector provides a DNA backbone with elements for replication, selection and, when required, expression.

4. Assemble the construct

DNA fragments are joined using a suitable assembly method. The main approaches are described below.

5. Introduce the construct into a host cell

Bacterial cells are commonly transformed for plasmid propagation. Eukaryotic cells may be transfected when the aim is expression or functional testing.

6. Select and screen

Selection identifies cells likely to contain the construct. Screening and sequence verification confirm the insert, orientation and intended sequence.

7. Use or analyse the DNA

The verified construct can be stored, modified, used in an assay or transferred to an expression system.

Molecular Cloning and DNA Assembly

While molecular cloning refers to the broader, end-to-end workflow of creating, propagating, and verifying a recombinant DNA construct, DNA assembly is specifically the central construction step where selected fragments are physically joined together.

Choosing the right cloning strategy depends heavily on your specific construct and its ultimate purpose. Practical factors, such as insert size, sequence constraints, vector architecture, the need for a scarless construct, and whether the DNA is planned for propagation or expression – all influence this choice. ⁶

For a more detailed discussion of how construct design influences cloning strategy, see my article on recombinant DNA construct design.

Depending on these factors, you typically choose between a few main assembly routes:

Restriction-enzyme and ligase cloning: This established method uses restriction enzymes to cut DNA at defined recognition sites and DNA ligase to paste compatible ends together. It is highly effective provided both the vector and the simple insert contain suitable restriction sites.³

PCR-based and advanced assembly: If you are working with multiple fragments or require a precisely defined junction, PCR (Polymerase chain reaction) can be used to amplify a gene of interest before an assembly method, like Gibson Assembly or Golden Gate Assembly, joins the pieces into a vector. ²³

It is worth noting, however, that PCR amplification on its own is not considered molecular cloning, because it occurs entirely in vitro without propagating the DNA within a living cell.

DNA Delivery Methods

Once your construct is successfully assembled, the next distinct step is delivering it into an appropriate host cell. It is important to emphasize that these delivery methods are solely about transporting the genetic material into the cell, they do not assemble the recombinant DNA construct itself.

The terminology used for this process depends entirely on the host system and the delivery mechanism:

• Transformation typically describes the uptake of DNA by bacteria.
• Transfection generally refers to non-viral DNA delivery into eukaryotic cells.
• Transduction uses a viral vector or phage to deliver the genetic material.

History of recombinant DNA technology

Early recombinant-DNA work built on the discovery of restriction enzymes and on methods for joining DNA fragments. Landmark publications from Stanford and the University of California, San Francisco in 1972 and 1973 demonstrated that DNA sequences could be assembled and propagated in cells. The work of Paul Berg, Stanley Cohen, Herbert Boyer and other researchers helped establish the methods that became molecular cloning ⁸.

In 1975, scientists met at the Asilomar Conference to discuss biological safety and appropriate safeguards for recombinant-DNA research ⁹. Recombinant-DNA methods later supported the development of recombinant medicines, including human insulin, with Humulin approved by the FDA in 1982 as the first biosynthetic human insulin product and the first approved medical product derived from this technology ¹⁰.

Recombinant protein expression: a related application

Recombinant DNA technology creates and modifies DNA constructs. Recombinant protein expression is one specific application of those constructs. It begins when a construct contains the regulatory elements required for transcription and translation in a suitable host cell.

From a recombinant DNA construct to a recombinant protein

A host cell can replicate a recombinant DNA construct without producing a protein. To produce a functional protein, the construct must contain an expression cassette with regulatory sequences that the host cell can recognise. Expression depends on the promoter, coding sequence, translation signals, host-cell biology, culture conditions and overall process design.

The protein can then be evaluated for folding, disulfide-bond formation, glycosylation, aggregation, stability and activity. Yield is a process metric, while purity describes product or sample quality. These characteristics belong to the protein and its manufacturing process, not to the DNA molecule itself. DNA design, including codon usage, and host selection can influence the result.

Why CHO cells are used for some therapeutic proteins

Selecting the appropriate host cell is a critical decision that must be matched to the specific requirements of the target protein. While bacterial systems such as Escherichia coli (E. coli), yeast cells and insect expression systems remain important for producing certain products and for propagating plasmids, they often lack the processing machinery for more intricate molecules.

This is why mammalian cells, particularly Chinese hamster ovary (CHO) cells, are frequently chosen for manufacturing complex therapeutic proteins and antibodies. CHO cells are well established in the biopharmaceutical industry because they support folding, secretion and post-translational processing relevant to many complex molecules ⁷. Ultimately, the optimal system depends on the molecule in question and its required product characteristics.

Applications of recombinant DNA technology

Recombinant DNA technology enables a wide range of fields, with end products varying from basic research tools to genetically engineered crops. It is important to distinguish the engineered DNA construct – the genetic blueprint – from the final product, which is often a recombinant protein produced by a host cell. The following examples highlight how this foundational technology is applied across different sectors.

Research and diagnostics

Researchers use recombinant DNA to clone genes, test regulatory sequences, and analyze gene function. These constructs also serve as the foundation for producing laboratory reagents and diagnostic components, such as specific probes and antigens.

Recombinant therapeutic proteins and antibodies

Recombinant DNA is the starting point for manufacturing vital therapeutic proteins, including human insulin, growth hormone, erythropoietin, coagulation factor VIII, and tissue plasminogen activator.

Recombinant antibodies – such as monoclonal, bispecific, or custom-engineered formats – are a major and highly complex class of these therapeutics. For these products, the final active material is the recombinant protein. Their manufacture requires controlled expression and purification processes. For antibodies in particular, the process must also address chain pairing, folding, glycosylation and aggregation.

Gene therapy

Unlike protein therapeutics, gene therapy represents a distinct application of genetic engineering. Some gene-therapy approaches use recombinant DNA constructs or viral vectors to deliver a genetic payload to target cells. The therapeutic aim is to introduce, replace or regulate genetic information rather than administer a recombinant protein as the active product.

Vaccines and enzymes

Engineered host systems are also used to produce recombinant vaccine antigens, including hepatitis B surface antigen produced in yeast or mammalian cells for recombinant hepatitis B vaccines ¹¹. Similarly, recombinant DNA enables the production of industrial and food-processing enzymes, like recombinant chymosin, which can be produced by genetically engineered microorganisms for use in cheese manufacturing ¹².

Agriculture and transgenic organisms

In agriculture, recombinant DNA constructs are utilized to create genetically modified plants that express beneficial traits, such as insect resistance (e.g., Bt crops), herbicide tolerance or nutritional traits (e.g., Golden Rice) ¹³. In these scenarios, the relevant outcome is the modified organism or crop itself. Consequently, agricultural applications involve regulatory, environmental, and societal considerations that depend on the crop, trait and jurisdiction ¹³¹⁴.

Safety, ethics and regulation

The safety profile of a recombinant DNA project is highly contextual; it depends heavily on the specific sequence, vector, host, containment level, intended use, and route of exposure. Because of this, handling an isolated DNA construct, manufacturing a purified recombinant protein, or developing a live transgenic organism each raises entirely different safety considerations.

• Laboratory and Manufacturing Risks: Basic laboratory risks primarily involve unintended biological activity, contamination, misuse, or the accidental transfer of genetic material. When a project advances to product development, the focus shifts to stringent manufacturing controls to ensure identity, purity, and potency, while controlling host-cell impurities and assessing potential immunogenicity.
• Environmental and Ethical Considerations: Environmental applications necessitate a thorough assessment of ecological effects, persistence, and potential spread. Similarly, ethical discussions surrounding GMOs, germline genome editing, human genetic data, and dual-use research are undeniably important. However, these ethical questions should not be framed as generic disadvantages of every recombinant DNA experiment; their relevance is tied directly to the specific application and its potential consequences.
• Regulatory Frameworks: Regulatory requirements vary significantly by country and context. Research, agricultural release, food production, diagnostics, and medicinal products are governed by different legal frameworks ⁵¹³¹⁴. Therefore, compliance must be assessed based on the specific jurisdiction and product category, rather than treating oversight as a single, universal rulebook.

What evitria does in recombinant protein production

At evitria, we help research and biopharmaceutical teams transform defined antibody sequences or DNA constructs into purified recombinant antibodies ready for discovery, screening, and early development. Alongside our core antibody work, we offer tailored expression services, including our high-throughput antibody production service and bispecific antibody production service, for selected recombinant proteins.

We know firsthand that careful construct design is critical. Elements like promoter context, coding-sequence design, codon usage, signal-peptide selection, chain arrangement, and vector compatibility can all significantly influence overall yield, secretion, and proper antibody assembly. To efficiently test and produce these unique constructs, we rely on a robust CHO-based transient expression workflow.

Following expression, our team purifies the recombinant antibodies and conducts rigorous, project-specific analytical quality control. Depending on your project’s specific needs, this QC can include titer measurement, HPLC-SEC analysis to check purity and aggregation, CE-SDS to assess structural integrity, and endotoxin testing. Ultimately, our goal is to ensure the material you receive is fully optimized and ready for your downstream research and characterization.

Key takeaways

• Recombinant DNA is a deliberately assembled or modified DNA molecule.
• Molecular cloning constructs, propagates and verifies DNA; transformation is one possible delivery step.
• A recombinant protein is an expression product of a recombinant DNA construct, not the same thing as the construct itself.
• CHO cells are used for recombinant protein expression and bioprocessing.
• GMO and genome editing are related applications but are not synonyms for recombinant DNA technology.
• evitria is best presented as a specialised recombinant antibody expression and protein-production provider within this wider field.

1. National Human Genome Research Institute. (2026, August 26). Recombinant DNA technology. https://www.genome.gov/genetics-glossary/Recombinant-DNA-Technology ↩︎
2. Khan, S., Ullah, M. W., Siddique, R., Nabi, G., Manan, S., Yousaf, M., & Hou, H. (2016). Role of recombinant DNA technology to improve life. International Journal of Genomics, 2016, Article 2405954. https://doi.org/10.1155/2016/2405954 ↩︎
3. Green, M. R., & Sambrook, J. (2001). Molecular cloning: A laboratory manual (3rd ed.). Cold Spring Harbor Laboratory Press. https://catalog.nlm.nih.gov/permalink/01NLMINST/1fua1rm/alma9915882953406676 ↩︎
4. Walsh, G., & Jefferis, R. (2006). Post-translational modifications in the context of therapeutic proteins. Nature Biotechnology, 24(10), 1241–1252. https://doi.org/10.1038/nbt1252 ↩︎
5. National Institutes of Health. (n.d.). NIH guidelines for research involving recombinant or synthetic nucleic acid molecules. Retrieved August 26, 2026, from https://ehs.yale.edu/resource/nih-guidelines-for-research-involving-recombinant-or-synthetic-nucleic-acid-molecules-nih ↩︎
6. Casini, A., Storch, M., Baldwin, G. S., & Ellis, T. (2015). Bricks and blueprints: Methods and standards for DNA assembly. Nature Reviews Molecular Cell Biology, 16(9), 568–576. https://doi.org/10.1038/nrm4014 ↩︎
7. 7. Li, Z.-M., Fan, Z.-L., Wang, X.-Y., & Wang, T.-Y. (2022). Factors affecting the expression of recombinant protein and improvement strategies in Chinese hamster ovary cells. Frontiers in Bioengineering and Biotechnology, 10, 880155. https://doi.org/10.3389/fbioe.2022.880155 ↩︎
8. 8. National Human Genome Research Institute. (2013). 1972: First Recombinant DNA. https://www.genome.gov/25520302/online-education-kit-1972-first-recombinant-dna ↩︎
9. Berg, P., Baltimore, D., Brenner, S., Roblin, R. O., & Singer, M. F. (1975). Summary statement of the Asilomar conference on recombinant DNA molecules. Proceedings of the National Academy of Sciences, 72(6), 981–1984.https://doi.org/10.1073/pnas.72.6.1981 ↩︎
10. 10. U.S. Food and Drug Administration. (2024). 100 Years of Insulin. https://www.fda.gov/about-fda/fda-history-exhibits/100-years-insulin ↩︎
11. World Health Organization. (n.d.). Hepatitis B vaccine standardization. https://www.who.int/teams/health-product-policy-and-standards/standards-and-specifications/norms-and-standards/vaccine-standardization/hep-b ↩︎
12. U.S. Food and Drug Administration. (2018). Microorganisms & Microbial-Derived Ingredients Used in Food (Partial List). https://www.fda.gov/food/generally-recognized-safe-gras/microorganisms-microbial-derived-ingredients-used-food-partial-list ↩︎
13. U.S. Department of Agriculture. (n.d.). Agricultural Biotechnology Glossary; Regulation of Biotech Plants. https://www.usda.gov/farming-and-ranching/plants-and-crops/biotechnology/agricultural-biotechnology-glossary ↩︎
14. European Food Safety Authority. (n.d.). Genetically modified organisms. https://www.efsa.europa.eu/en/topics/genetically-modified-organisms ↩︎